Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC).

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Tjalf Ziemssen has received personal compensation for participating on advisory boards, trial steering committees, and data and safety monitoring committees, as well as for scientific talks and project support from: Almirall, Bayer, Biogen, BMS, Sanofi, Janssen, Merck, Novartis, Roche, Viatris, and Teva. Marie Groth and Benedict Rauser are employees of Novartis Pharma GmbH, Nuremberg, Germany. Tobias Bopp has received consulting fee and honoraria for lectures from Biogen, Celgene, Merck, Novartis, Pathios Therapeutics, Roche, Sanofi Genzyme, and Teva."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Novartis Pharma GmbH."

"Registration:: EU Clinical Trials Register: EudraCT 2020-005752-38 (www.clinicaltrialsregister.eu); ClinicalTrials.gov: NCT04792567 (https://clinicaltrials.gov)."